WCRF); Type 2 diabetes (T2D); body mass index (BMI); food frequency questionnaires (FFQ); hazard ratios (HRs); 95% confidence intervals (CIs) and reactive oxygen species (ROS). This article is protected by copyright. All rights reserved.
INTRODUCTION
There is growing consensus that obesity and related metabolic disorders such as Type 2 diabetes (T2D) represent important risk factors for a significant number of cancers. According to a recent report by the International Agency for Research on Cancer (IARC), there is sufficient evidence for obesity to be classified as a causal risk factor for cancers of the esophagus (adenocarcinoma), stomach cardia, colorectum, liver, gallbladder, pancreas, breast (postmenopausal), corpus uteri, ovary, kidney, meningioma, thyroid and multiple myeloma (1) , while T2D is an established risk factor for cancers of the colorectum, pancreas, liver, gallbladder, breast, and corpus uteri (2) . It has been predicted that at least 5.7 % (approximately 804,100 cases) of the global cancer burden in 2012 could be attributed to high body mass index (BMI) and T2D combined (3) .
Emerging evidence suggests that metabolic factors which typically accompany obesity, such as insulin resistance and hyperinsulinaemia, may be more relevant risk factors for some cancers than adiposity per se. For example, in analyses conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Women's Health Initiative (WHI), participants with higher insulin levels were at greater risk of developing colorectal and breast cancer, compared to those with normal insulin levels, regardless of body fatness (4) (5) (6) (7) . These studies indicate that metabolic factors such as hyperinsulinemia are an important determinant of some common cancers, independent of overall adiposity.
Basal metabolic rate (BMR) is defined as the daily rate of energy metabolism required to preserve the integrity of vital functions in both waking and resting states (8) and represents 35 to 70% of the total energy requirement of an individual. It has been shown that BMR is higher in younger age, in males, and in individuals with greater height, weight and lean body mass (9) . BMR has also been shown to be positively associated with pro-inflammatory status among both normal weight and overweight individuals (10) , suggesting it may be a marker of metabolic health, independent of adiposity.
Consistent with this, in a cohort study of elderly individuals, higher BMR was found to be associated with greater mortality risk, independent of body mass index (BMI) (11) . Similarly, a cohort study of Pima Indians found that every 100 kcal increase in daily energy expenditure was associated with 29% higher risk of natural death, regardless of participants' body weight (12) . To date, only one study has investigated the association between BMR and cancer risk, and specifically breast cancer, using data from the National Health and Nutrition Examination Survey (NHANES) in the United States. That study found that postmenopausal women in the upper quintile for BMR had significantly greater breast cancer risk compared to those in the lower quintile (13) . However, it is currently unknown if BMR is associated with risk of other cancers and whether these relationships are independent of adiposity.
We therefore conducted a comprehensive investigation of predicted BMR and its association with the risk of 13 cancers in the European Prospective Investigation into Cancer (EPIC) a prospective cohort of over 520,000 participants with baseline data on BMR. The large number of recorded incident cancer cases afforded sufficient statistical power to investigate the BMR and cancer relationships according to sex and by strata of body habitus (normal weight and overweight).
The European Prospective Investigation into Cancer and Nutrition (EPIC) is an ongoing multicentre prospective cohort study, designed to investigate the associations between diet, lifestyle, genetic and environmental factors and various types of cancer. A detailed description of this cohort study has been published elsewhere (14, 15) . Briefly, a total of 521,324 participants (~70% female) were recruited between 1992 and 2000 from 23 centers across ten European countries (Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom). All study participants provided written informed consent. Ethical approval for the EPIC study was obtained from the review boards of the International Agency for Research on Cancer and local participating centres: National Committee on Health Research Ethics (Denmark); Comité de Protection des Personnes (France); Ethics Committee of the Heidelberg University Medical School (Germany); Ethikkommission der Landesärztekammer Brandenburg Cottbus (Germany); University of Athens Medical School (Greece) Comitato Etico Indipendente, Fondazione IRCCS Istituto Nazionale dei Tumori (Italy); Human Genetics Foundation Torino Ethics Committee (Italy); Medical Ethical Committee (METC) of the University Medical Center Utrecht (the Netherlands); Regional Ethical Committee for Northern Norway and the Norwegian Data Inspectorate (Norway); Comité de Ética de Investigación Clínica (Spain); Ethics Committee of Lund University (Sweden); Umea Regional Ethical Review Board (Sweden); Norwich District Ethics Committee (UK); Scotland A Research Ethics Committee (UK); and the Imperial College Research Ethics Committee (UK). The current study included participants with information at baseline on sex, age, weight, and height, which were used to compute the basal metabolic rate (BMR). Participants were excluded if they were: pregnant at baseline (n=547); had cancer at recruitment (n=25,184); had missing follow-up information (n=4,148); had missing baseline questionnaire data (n=6,259); self-reported thyroid disease as this may affect individuals' BMR (n=16,705); or were within the extreme ranking (top and bottom 1%) of the ratio energy intake/energy requirement (n=9,573). This cut-off point for the ratio of energy This article is protected by copyright. All rights reserved.
MATERIALS AND METHODS

Study Participants
intake/energy requirement is a routine exclusion made on the EPIC baseline questionnaire on all EPIC analyses. A more stringent cut-off point (top and bottom 5%) was performed with no change in the study results (data not shown).
Follow-up for Cancer Incidence
Incident cancer cases were identified using cancer registries in Norway, Sweden, United Kingdom, Spain, Italy, the Netherlands, and Denmark. For other countries, such as France, Germany and Greece, incident cancer cases were identified during follow-up from a combination of sources including cancer and pathology centres, health insurance records and active follow-up of study subjects. All countries followed a detailed protocol for the collection and standardization of clinical and pathological data on each cancer site (16) (17) (18) (19) . The end of follow-up was established as the latest Whenever possible, morphology information was used to classify the malignant tumours according to histological type, as for example, esophageal adenocarcinoma and hepatocellular carcinoma.
At baseline, information on lifestyle, dietary intake and medical information as well as demographics and anthropometric data were collected. Lifestyle and medical history questionnaires were used to obtain information on education, smoking status and intensity, alcohol consumption, diabetes and women's health (menopausal status, oral contraceptive use, hormone replacement use, age at menarche and age at first full-term pregnancy). Physical activity levels were estimated using a questionnaire focused on past-year physical activity in occupational, leisure and household domains and classified according to the validated Cambridge physical activity index (21). Validated country/centre-specific dietary questionnaires were used to obtain information on dietary intake (energy, dietary fibre, fish and shellfish, meat and processed meat intake). The types of dietary questionnaires used varied according to the study centre, including semi-quantitative food frequency questionnaires (FFQ) with or without an estimation of individual average portion size and diet history questionnaires combining a FFQ and 7-day dietary recalls (15) . Body weight and height were measured in all centres, except for Oxford, France and Norway where these were self-reported.
Anthropometric characteristics were measured by trained observers using standardized methods (15) .
Body weight was measured by electronic digital scales, with subjects wearing only light underwear and after emptying the bladder. Height was measured to the nearest 0.1 cm using a flexible anthropometers (22) . Assessed weight and height were used to calculate BMI defined as weight in kilograms divided by height in metres squared (kg/m 2 ).
Assessment of predicted Basal Metabolic Rate
Predicted BMR at baseline was calculated for each participant using the WHO/FAO/UNU (23) equations, which are based on Schofield equations (24). This method calculates BMR using gender and age-specific equations (18 to 30 years; 31 to 60 years and >60 years) as shown in S1 Table. The equations also take into account an individuals' weight and height. This method is one of the most This article is protected by copyright. All rights reserved.
Baseline Characteristics
frequently used to assess BMR in dietary studies and according to the experts of the European Food Safety Authority (EFSA), it can be considered as equally valid as those more recently developed (25) .
For comparison, BMR was also assessed using other methods including the Oxford (8), Harris-Benedict (26) and Mifflin St Jeor (27) equations that also use sex, age, weight and height to predicted BMR (S1 Table) .
Statistical Analysis
Pearson correlation coefficients between BMR defined by WHO/FAO/UNU and the other BMR equations were derived. The Pearson correlation coefficients between BMR, BMI, weight and height were also assessed. The relationships between BMR and BMI with cancer risk were investigated using multivariable Cox proportional hazards regression models (Hazard ratio [HR] and 95% confidence intervals [95%CI]). Time at entry was age at recruitment and exit time was age at cancer diagnosis, end of follow-up, lost to follow-up or death, whichever came first. Models were stratified by country and age at recruitment (in 1-year categories) to control for age and country-specific effects. Sex-specific BMR and BMI continuous variables were normalised to 1-standard deviation, in order to allow the comparison of the associations of these exposures with cancer risk. Multivariable models were adjusted for other cancer risk factors, namely: education (none; primary school; technical/professional school; secondary school; and longer education), physical activity index (inactive; moderately inactive; moderately active; and active), smoking (never; former; and smoker), alcohol consumption (g/d), dietary intakes related to cancer risk (energy, dietary fibre, fish and shellfish, meat and processed meat intake), self-reported diabetes at recruitment (yes; no), and menopausal hormone therapy (never; ever), for women only. Further adjustment for other risk factors was also tested such as dairy intake of calcium (g/d), but since no difference was observed in the HRs, these were excluded from the final models. For female-specific cancer sites (e.g. cancers of the reproductive system) the models were further adjusted for menopausal status (premenopausal; postmenopausal; perimenopausal; and surgical postmenopausal) oral contraceptive use (never; ever), age at menarche (y) and age at first full-term pregnancy (y). Chi-squared tests were performed to evaluate whether the parameters of BMR and BMI for each cancer were significantly different (pheterogeneity). In an attempt to investigate the relationship between BMR and cancer risk, independent of BMI, BMR residuals were computed from a linear regression of BMR on BMI, height, age, country and sex. BMR residuals were normalised to 1-standard deviation and investigated in relation to cancer risk in multivariable Cox proportional hazards regression models, which were further adjusted for BMI. We also examined the relationship between BMR and cancer risk among normal weight (BMI<25 kg/m 2 ) and overweight/obese groups (BMI≥25 kg/m 2 ), and assessed heterogeneity between these subgroups and BMR by using interaction terms (multiplicative scale); the statistical significance of the cross-product terms was evaluated using the likelihood ratio test. This stratified analysis was also repeated using BMR residuals.
All analyses were repeated separately according to menopausal status for female reproductive cancers.
Women contributed person-time to the 'premenopausal model' until their age of menopause onset and from their age of menopause onwards to the 'postmenopausal model'. Menopause age was collected at baseline for postmenopausal women. If missing, and if women were premenopausal at baseline, then menopause age was set as 55 years. Sensitivity analyses were performed excluding participants who self-reported chronic diseases (heart disease, diabetes, and stroke) and who self-reported weight and height at recruitment. The influence of preclinical disease on the results was assessed by excluding participants diagnosed within the first 2 years of follow-up. Statistical tests used in the analysis were all two-sided, and a p-value of <0.05 was considered as statistically significant.
Statistical analyses were conducted using Stata v11.0 and the figures were constructed using R.
Data Availability
EPIC data and biospecimens are available for investigators who seek to answer important questions on health and disease in the context of research projects that are consistent with the legal and ethical standard practices of IARC/WHO and the EPIC Centres. The primary responsibility for accessing the data belongs to the EPIC centres that provided them. The use of a random sample of anonymised data from the EPIC study can be requested by contacting epic@iarc.fr. The request will then be passed to members of the EPIC Steering Committee for deliberation.
RESULTS
A total of 141,295 men and 317,613 women with a mean age of 52 and 50 years at baseline, respectively, were included in the analysis. The mean follow-up time was 14 years (SD 4.0). Both male and female participants with higher BMR were taller, had higher BMI and reported greater intake of fish and shellfish and red and processed meat ( Table 1) . Male participants with higher BMR were more likely to report higher caloric and alcohol intake compared to those in the lowest category, while for female participants an opposite trend was observed. Female participants with higher BMR also had lower attained education level; earlier age at menarche and earlier age at first full pregnancy.
Predicted BMR calculated using the WHO/FAO/UNU equation was strongly correlated (r>.96) with those derived from the other BMR equations. Correlation coefficients between predicted BMR and BMI were 0.53 among men and 0.77 among women (S2 Table) .
The hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between BMR and risk for cancers at different anatomical sites, and their comparison with HRs and 95%CIs for the associations of cancer endpoints with BMI, are displayed in Figures 1 (men) and 2 (women) . Results for colon cancer showed that a one standard deviation increase in BMR was associated with 29% (95%CI 1.21; 1.38) higher risk for men and 8% (95%CI 1.03; 1.13) higher risk for women (similar patterns of results were observed for proximal and distal colon cancers). For pancreatic cancer, a one standard deviation increase in BMR was associated with 13% (95%CI 1.01; 1.26) and 17% (95%CI 1.08; 1.26) higher risk in men and women, respectively. Similarly, a one standard deviation increase in BMR was associated with an increased risk for kidney cancer in men (HR1-sd 1.40; 95%CI 1.25;
1.55) and in women (HR1-sd 1.19; 95%CI 1.08; 1.30). For gallbladder cancer, one standard deviation increase in BMR was associated with 98% (95%CI 1.18; 3.32) higher risk in men and 31% (95%CI 1.07; 1.61) higher risk in women. BMR was also positively associated with risks of stomach cardia (HR1-sd: 1.34, 95%CI 1.08; 1.67), meningioma (HR1-sd: 1.21, 95%CI 1.08; 1.35) and thyroid (HR1-sd:
1.17, 95%CI 1.07; 1.28) cancers among women. For men, BMR was positively associated with risks of HCC (HR1-sd: 1.38; 95%CI 1.13; 1.68), esophageal adenocarcinoma (HR1-sd: 1.49; 95%CI 1.21;
1.83), and multiple myeloma (HR1-sd: 1.15; 95%CI 1.05; 1.26). BMR remained statistically significant associated with most cancer sites when the multivariable models used BMR residuals and were further adjusted for BMI ( Table 2) .
For female-specific cancers, one standard deviation increment in BMR was associated with a 8% (95%CI 1.08; 1.10) higher risk of breast cancer, 39% (95%CI 1.33; 1.47) higher risk of endometrial cancer, and 8% (95%CI 1.01; 1.15) higher risk of ovarian cancer. When these analyses were stratified by menopausal status, the associations were only evident among postmenopausal women (S3 Table) .
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Association of predicted BMR with Cancer Risk
The associations between BMI and risks of individual cancers were generally similar to those found for BMR (Figures 1 and 2) . However, for breast cancer, compared to BMI, BMR was more strongly associated with risk (p-heterogeneity=0.014) (Figure 2) . For cancers of the proximal colon (women only), stomach cardia, and thyroid (both men only) positive relationships were only found with BMR, but not with BMI; however, the heterogeneity did not meet the threshold of significance (p-heterogeneity>0.05) (Figures 1 and 2) . Table   2 ). For overweight/obese men, BMR was positively related to risks of all cancers, although the positive relationships observed for stomach cardia, gallbladder, meningioma, thyroid and rectal cancers did not reach the threshold of significance. For overweight/obese women, BMR was positively and significantly associated with pancreatic (HR1-sd: 1.17; 95%CI 1.05; 1.31), kidney (HR1sd: 1.16; 95%CI 1.02; 1.32), breast (HR1-sd: 1.07; 95%CI 1.03; 1.11), endometrial (HR1-sd: 1.41; 95%CI 1.31; 1.51), and ovarian (HR1-sd: 1.12; 95%CI 1.02; 1.24) cancers ( Table 3) . BMR remained statistically significantly associated with most cancer sites when the stratified analyses were repeated using BMR residuals ( Table 4 ). When these analyses were stratified by menopausal status, the associations were only evident among postmenopausal women, even when using BMR residuals (S4 Table) . For the majority of cancer sites, there was no heterogeneity in the association of BMR with cancer risk among individuals with normal weight or with overweight or obesity. The exception was for breast cancer, where higher BMR was more strongly associated with breast cancer among women with normal weight compared to those with overweight or obesity (P-heterogeneity=0.002).
BMR and Cancer Risk in Normal Weight and Overweight/Obese Groups
Sensitivity analysis
The results were largely unchanged after cancer cases which occurred during the first 2 years of follow-up were excluded (S5 Tables). Also, sensitivity analyses excluding participants who selfreported chronic diseases (S6 Tables) and who self-reported weight and height (S7 Tables) at recruitment showed similar results.
DISCUSSION
In this multi-country prospective cohort analysis, higher predicted BMR was associated with greater risk for most cancers that have been linked with obesity. Importantly, among normal-weight individuals (BMI<25kg/m 2 ), higher BMR was associated with a greater risk of colon, pancreas, thyroid, esophageal adenocarcinoma, postmenopausal breast, and endometrial cancer. These results suggest that BMR may identify subgroups of the population who are at greater risk of these malignancies that would not have otherwise been identified solely by BMI.
The reprogramming of energy metabolism is one of the hallmarks of cancer and metabolic transformation is a key event in tumorigenesis. Markers of metabolic health such as insulin regulation or of adiposity such as waist circumference and BMI are risk factors for a number of different cancers. In this analysis, we found that predicted BMR, which reflects whole body energy metabolism, was associated with the development of specific cancers, even among lean individuals. In terms of potential biological mechanisms, individuals with higher BMR require greater cellular energy generation to meet their higher energy and metabolic requirements. Enhanced aerobic glycolysis may lead to a greater reactive oxygen species (ROS) generation, a by-product of cellular respiration. Although ROS production and detoxification are usually well balanced, a shift in this equilibrium may lead to ROS in excess promoting oxidative stress (28) and the accumulation of oncogenic DNA defects as well as the activation of oncogenic signalling pathways (29) . In fact, a recent review suggested that higher BMR could increase cancer risk by means of higher oxidative stress and mutational rates (30) . Increased ROS has also been linked to many metabolic alterations, such as insulin resistance (31) , decreases in adiponectin and increased expression of pro-inflammatory cytokines including TNFα and IL-6 (32) . In line with this, BMR has been positively associated with levels of insulin and Type 2 diabetes (33) (34) (35) , although conflicting results have also been found (36, 37) . Previous studies have shown that these metabolic alterations can drive cancer development in both normal weight (4-7) and overweight individuals (33) (34) (35) , which are in agreement with the results from the current study, showing that BMR was associated with cancer risk independent of BMI.
The potential link between BMR and cancer may also explain why taller individuals have higher risk of certain cancers (38) (39) (40) (41) . Taller individuals have a greater requirement of energy metabolism due to a higher number of cells and organ mass. Although the underlying biological mechanisms are still not completely elucidated, it is suggested that the number of cells may influence the effect of height on cancer risk, as it would also increase the opportunities for mutations and malignant tumour development (42, 43) . Higher exposure to growth hormones (GH) and insulin-like growth factor-1 (IGF-1) during early growth, which might be activated by overnutrition during different stages of child development, may also be relevant (44) (45) (46) (47) , and it may differ by anatomical subsites (39) .
To our knowledge, this is the first investigation on the association between predicted measures of BMR and multiple cancers in a large-scale prospective cohort setting. The long term follow-up and high number of incident cancer cases recorded allowed us to investigate the BMR and cancer associations by sex and body size groups. However, some limitations of the current study should also be considered. First, BMR was only predicted and was assessed using WHO/FAO/UNU equations, which may overestimate actual BMR (8) , particularly among overweight and obese individuals (48) .
This may occur as BMR equations take into account total body mass and do not make a distinction between lean and fat mass which differ metabolically. However, in our analysis BMR calculated using the WHO/FAO/UNU equation was strongly correlated with BMR predicted by Mufflin St Jean equation, which has been considered the most accurate for overweight and obese individuals (49) .
Although indirect calorimetry may be a more reliable tool to measure BMR, it is expensive compared to predictive equations and not realistic for large-scale population-based studies (9, 50) . It is also important to note that only predicted BMR at baseline has been assessed in EPIC, while multiple measurements over time may allow a more precise assessment of the impact of BMR on cancer risk. Furthermore, the models were not adjusted for body fat-free mass, a factor that influences BMR (9), as this variable was not available. Another potential limitation is the quantity of missing data for selfreported thyroid disease in EPIC, which is also an important factor that affects an individual's BMR.
However, given that only ~10% of the European population suffers from clinically manifest thyroid disease (51) , it is unlikely that failure to capture this information would have substantially affected our results.
Further, as BMR is a composite function of age, sex, height and weight, which are well known risk factors for cancer, it is possible that BMR may be capturing part of the effect of these variables on cancer. In an attempt to disentangle the association between predicted BMR and BMI, and to explore whether BMR captures additional information beyond BMI that may be relevant for cancer prediction, we repeated the analysis using BMR residuals and further adjusted the models by BMI or stratified them by BMI group. The results confirmed an association between BMR and cancer risk beyond adiposity.
In conclusion, higher predicted BMR was associated with most obesity-related malignancies and may be an indicator of a metabolic phenotype associated with cancer risk. Importantly, among normalweight individuals, higher BMR was related to greater risks of cancers of the colon, pancreas, thyroid, postmenopausal breast, endometrium, and esophageal adenocarcinoma. For these cancer sites, BMR may be a useful predictor of cancer risk regardless of overall adiposity. Further understanding of the role of metabolic dysfunction on cancer risk is needed. Additionally, the replication of these analyses using BMR measured by indirect calorimetry and adjusting for body composition (e.g. fat-mass and fat-free mass) could provide more robust evidence for the association between BMR and cancer risk.
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